Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Total Non-Current Liabilities (2016 - 2025)

Marimed (MRMD) has disclosed Total Non-Current Liabilities for 15 consecutive years, with $137.8 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 6.56% to $137.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $137.8 million through Dec 2025, up 6.56% year-over-year, with the annual reading at $137.8 million for FY2025, 6.56% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $137.8 million at Marimed, up from $136.5 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $137.8 million in Q4 2025, with the low at $37.5 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $89.3 million, with a median of $89.2 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities tumbled 36.32% in 2021, then surged 87.69% in 2023.
  • Over 5 years, Total Non-Current Liabilities stood at $49.1 million in 2021, then increased by 16.27% to $57.1 million in 2022, then soared by 87.69% to $107.1 million in 2023, then grew by 20.76% to $129.3 million in 2024, then increased by 6.56% to $137.8 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $137.8 million, $136.5 million, and $131.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.